National Research (NASDAQ:NRCIA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday.
According to Zacks, “National Research Corporation offers analytics and insights that facilitate revenue growth, patient, employee, customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. Its services include capture, interpretation, transmittal and benchmarking of critical data elements from various healthcare consumers. National Research Corporation is headquartered in Lincoln, Nebraska. “
Separately, BidaskClub upgraded National Research from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th.
In other news, CEO Michael D. Hays sold 1,602,399 shares of the business’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $39.03, for a total value of $62,541,632.97. Following the completion of the transaction, the chief executive officer now owns 5,261,410 shares in the company, valued at $205,352,832.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 37.54% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the stock. Kayne Anderson Rudnick Investment Management LLC increased its position in National Research by 3.6% during the third quarter. Kayne Anderson Rudnick Investment Management LLC now owns 2,070,194 shares of the business services provider’s stock valued at $78,046,000 after acquiring an additional 71,648 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in National Research by 1.3% during the third quarter. Dimensional Fund Advisors LP now owns 605,856 shares of the business services provider’s stock valued at $22,841,000 after purchasing an additional 7,666 shares during the period. BlackRock Inc. grew its holdings in National Research by 0.6% during the fourth quarter. BlackRock Inc. now owns 476,279 shares of the business services provider’s stock valued at $17,765,000 after purchasing an additional 2,620 shares during the period. Conestoga Capital Advisors LLC grew its holdings in National Research by 7.5% during the fourth quarter. Conestoga Capital Advisors LLC now owns 453,436 shares of the business services provider’s stock valued at $16,913,000 after purchasing an additional 31,505 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in National Research by 27.1% during the fourth quarter. Renaissance Technologies LLC now owns 289,900 shares of the business services provider’s stock valued at $10,813,000 after purchasing an additional 61,900 shares during the period. Institutional investors own 25.40% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “National Research (NRCIA) Downgraded by Zacks Investment Research” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/14/national-research-nrcia-downgraded-by-zacks-investment-research.html.
National Research Company Profile
National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers, payers and other healthcare organizations. The Company operates through six segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Connect.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.